Related Experiment Videos
Protein tyrosine kinases: structure, substrate specificity, and drug discovery
F A al-Obeidi1, J J Wu, K S Lam
1Selectide Corporation, A Subsidiary of Hoechst Marion Roussel, Inc., Tucson, AZ 85737, USA.
Biopolymers
|November 17, 1998
Summary
Protein tyrosine kinases (PTKs) are vital for cell regulation and implicated in diseases. Researchers are developing specific PTK inhibitors, with some now in clinical trials for conditions like cancer.
Area of Science:
- Biochemistry and Molecular Biology
- Enzymology
- Cell Signaling
Background:
- Protein tyrosine kinases (PTKs) regulate critical cellular processes.
- Dysfunctional PTKs are linked to various diseases, including cancer, psoriasis, and osteoporosis.
- PTK kinase domains share conserved structures despite diverse primary sequences.
Purpose of the Study:
- To review the progress in identifying specific substrate motifs for PTKs.
- To highlight the development of PTK inhibitors based on identified substrates.
- To discuss advancements in PTK assay technologies and small molecule inhibitors.
Main Methods:
- Utilizing combinatorial peptide library methods to identify PTK substrate motifs.
- Developing pseudosubstrate-based peptide inhibitors.
- Characterizing small molecule inhibitors targeting the ATP binding site of PTKs.
Main Results:
- Specific peptide substrates for PTKs with mid-micromolar Km values have been identified.
- Potent and selective pseudosubstrate-based peptide inhibitors with low-micromolar IC50 values have been developed.
- Numerous small molecule PTK inhibitors targeting the ATP-binding site have been created, with some entering clinical trials.
Conclusions:
- Advances in identifying PTK substrates have enabled the development of targeted inhibitors.
- PTK inhibitors show promise for treating diseases like cancer, with several in clinical development.
- High-throughput assay technologies are accelerating PTK inhibitor discovery.